AMD logo Advanced Micro Devices +
Advanced Micro Devices
+

Advanced Micro Devices (AMD) Business News

Track Advanced Micro Devices in real time with a live news feed covering Advanced Micro Devices stock news, official press releases, company announcements, and an archive of historical Advanced Micro Devices news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

AMD CEO Shares Trump-Xi Expectations at IMPERIA Summit: NYSE Content Update

PRNewsWire

8:55 AM | Thursday | Sep 24, 2026

news photo
Loading...

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.

Read full article redirect
8:55 AM | Thursday | Sep 24, 2026

AMD CEO Shares Trump-Xi Expectations at IMPERIA Summit: NYSE Content Update

PRNewsWire

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.

Read full article arrow
News Thumbnail
8:46 AM | Monday | Sep 21, 2026

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine

Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced results from a production deployment of the open-source OpenFold3 structure prediction model, run with engineering partners AMD and Vultr on Vultr Kubernetes Engine and Vultr Cloud GPU powered by AMD Instinct™ MI325X GPUs and delivered through AMD Inference Microservices (AIM). It also served as an independent validation of AIM for OpenFold3 in a production life-sciences.

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Sep 17, 2026

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

GlobeNewsWire

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Sep 15, 2026

SiFive and AMD Collaborate to Optimize AMD ROCm on RISC-V Datacenter Servers

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Today at the AI Infra Summit, SiFive, Inc., and AMD showcased a demonstration of AMD ROCm™ (Learn more) running on SiFive's recently announced BigSky Datacenter Development Platform. In a demonstration-only system, the companies showed the ability to run the modern Gemma4-E2B LLM model using ROCm 10.0 on SiFive servers powered by the SiFive Performance™ P870-D CPUs acting as the head node, and AMD Radeon™ AI PRO R9700 GPUs driving the inference offload.
Thi.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Sep 15, 2026

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

GlobeNewsWire

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company's application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to potentially be the first TKI approved for wet AMD BEDFORD, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the successful completion of its Pre-New Drug Application (NDA) Meeting with the U.S.
Food and Drug Administration (FDA) for... Read more

Read full article arrow
News Thumbnail
7:15 AM | Monday | Aug 31, 2026

AMD, Cisco and HUMAIN Expand Saudi Arabia's AI Infrastructure as AMD Instinct Systems Go Live

GlobeNewsWire

News Highlights HUMAIN is now delivering production AI compute in Saudi Arabia powered by AMD Instinct™ MI355X GPUs, AMD EPYC™ CPUs and Cisco Silicon One-based AI networking to deliver the performance, scale and resilience necessary for next-generation workloads.  AMD, Cisco and HUMAIN plan to deploy up to 250 MW of AI infrastructure as part of the next phase of the buildout beginning in 2027.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | Aug 26, 2026

Kodiak AI and AMD Collaborate to Advance Computing Power for Driverless Trucking

GlobeNewsWire

MOUNTAIN VIEW, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kodiak AI, Inc. ("Kodiak”) (Nasdaq: KDK), a leading provider of physical AI-powered autonomous driving technology, today announced a collaboration with AMD to implement its AMD EPYC ™ Series processors to power Kodiak's seventh-generation autonomous truck platform.

Read full article arrow
News Thumbnail
7:00 AM | Monday | Aug 17, 2026

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

GlobeNewsWire

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort – – LUGANO demonstrated clinically meaningful results that reinforce DURAVYU's potential to improve the treatment paradigm in wet AMD, with compelling key secondary endpoints, including reduction in treatment burden, supplement-free rates, favorable safety profile with redosing, and strong anatomic control through Week 56 compared to on-label aflibercept – – 42% reduction in treatment burden achieving superiority versus on-label aflibercept (nominal p-value of

Read full article arrow
News Thumbnail